Dual GLP-1/Glucagon Agonist For NASH

A peptide-based dual GLP-1/glucagon receptor agonist designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis (NASH). NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD), is a complex disease with multiple metabolic pathways involved in the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, leading to fibrosis or eventually liver cancer. Because ALT-801 acts on the upstream initiators of NASH, it may be able to correct the metabolic dysfunction at the heart of NASH as demonstrated in one of the best preclinical models of the disease.